We focused on investigating the long-term effectiveness and safety of two distinct SGLT-2i, empagliflozin and dapagliflozin, in inadequately controlled T2DM in combination with metformin, other oral antidiabetic agents or insulin, according to the prescription protocols approved in Romania during the studied period. This evidence concerns the gene INS and type 2 diabetes mellitus.